IDDF2021-ABS-0080 96-week efficacy and safety of tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) switch vs. continued TDF treatment among virologically-suppressed hepatitis B patients of asian ethnicity

Authors :: Sang Hoon Ahn
Alnoor Ramji
Scott Fung
Chi-Yi Chen
Hie-Won Hann
Yang Zhao
Shalini Sethi
Wan-Long Chuang
Ho Bae
Leland J. Yee
John F. Flaherty
Carol Yee Kwan Chan
Young-Suk Lim
Xiaoli Ma
Pietro Lampertico
Yoon Jun Kim
Jia-Horng Kao
Anuj Gaggar
Edward Tam
Henry Lik-Yuen Chan
June Sung Lee
Source :: Clinical Hepatology.
Publication Year :: 2021
Publisher :: BMJ Publishing Group Ltd and British Society of Gastroenterology, 2021.

Subjects :: medicine.medical_specialty
Tenofovir
business.industry
Internal medicine
medicine
Asian ethnicity
Hepatitis B
medicine.disease
business
Tenofovir alafenamide
Gastroenterology
medicine.drug

Full Text Access

Tools